Your session is about to expire
← Back to Search
VRC-MALMAB0114-00-AB for Malaria (VRC 614 Trial)
VRC 614 Trial Summary
This trial is testing a drug to prevent malaria infection. Healthy adults ages 18-50 who have never had malaria can participate. The trial will last 2-6 months.
VRC 614 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowVRC 614 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 1 trial • 32 Patients • NCT05019729VRC 614 Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Frequently Asked Questions
Is the age criterion for participation in this experiment limited to those under 30?
"According to the study's inclusion criteria, invited patients must be between 18 and 50 years of age. For younger individuals (under 18), there are 68 clinical trials that may meet their needs; 34 such studies exist for those over 65."
Is participation in this experiment open to the public?
"For entry into this trial, potential participants must have malaria and be between the ages of 18 to 50. Up to 32 members may partake in the study."
Is the medication VRC-MALMAB0114-00-AB safe to administer to patients?
"Due to the experimental nature of VRC-MALMAB0114-00-AB, our team assesses its safety at a 1. This is because it has only been through one phase of testing and there is limited evidence supporting efficacy or safety."
Is this medical trial currently accepting new participants?
"Clinicaltrials.gov indicates that this medical trial, initially uploaded on September 13th 2021 and revised October 13th 2022, is no longer seeking participants at the present moment. However, there are 99 other trials actively recruiting patients."
Share this study with friends
Copy Link
Messenger